Tramadol Hydrochloride Tablet, Extended Release
Product Images NDC 71205-656

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tramadol Hydrochloride (NDC 71205-656). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tramadol-figure1 (Tramadol Figure1)

A pharmacokinetic curve displaying Tramadol concentration (ng/mL) over 24 hours comparing Tramadol Hydrochloride Extended-Release Tablets 200 mg once daily (q.d.) and Tramadol Immediate Release (IR) Tablets 50 mg every 6 hours (q6h). The y-axis shows Tramadol concentration and the x-axis shows time in hours. The graph illustrates the differences in blood levels between the two dosing regimens.*

FDA Label Image

Tramadol-figure2 (Tramadol Figure2)

A pharmacokinetic concentration-time graph comparing M1 metabolite levels (ng/mL) over 24 hours between two Tramadol formulations: extended-release tablets 200 mg once daily and immediate-release tablets 50 mg every 6 hours. The x-axis shows time in hours, and the y-axis shows M1 concentration.*

FDA Label Image

Tramadol-figure3 (Tramadol Figure3)

A line graph titled 'Tramadol Hydrochloride Extended-Release Tablets Study 023 WOMAC Pain Responder Analysis' showing the percent of patients achieving various response thresholds of pain improvement. The x-axis represents the response threshold in percent improvement from baseline (0 to 100%), and the y-axis shows the percent of patients achieving response (0 to 60%). Multiple lines compare response rates for different dosages of tramadol hydrochloride extended-release tablets (100 mg, 200 mg, 250 mg, 300 mg, 400 mg) against a placebo.*

FDA Label Image

Tramadol-figure4 (Tramadol Figure4)

Line graph showing the percentage of patients achieving various levels of response threshold for Tramadol Hydrochloride Extended-Release Tablets compared to placebo in an arthritis pain intensity study. The x-axis represents response threshold as percent improvement from baseline, and the y-axis shows the percent of patients achieving response. The graph illustrates that a higher percentage of patients achieved response across thresholds with Tramadol Hydrochloride Extended-Release Tablets than with placebo.*

FDA Label Image

71205-656-30 (Tramadol Label 300mg)

Tramadol HCl 300 mg extended-release (ER) tablets packaging label by Proficient Rx LP. The label states a count of 30 tablets and includes drug classification as Schedule C-IV. Tablets are described as white, round, biconvex with beveled edges and a release portal, imprinted with '537'. Manufacturer listed as Sun Pharmaceutical Industries Ltd., India. Storage instructions given as 20°-25°C (68°-77°F). Various barcodes and a QR code are also visible on the label.*

FDA Label Image

Tramadol-structure (Tramadol Structure)

Chemical structure diagram of tramadol hydrochloride showing its molecular configuration including a cyclohexane ring, methoxyphenyl group, hydroxyl group, dimethylamine side chain, and hydrochloride salt.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.